Tonix Pharmaceuticals Holding Corp. (TNXP)
| Market Cap | 160.68M -40.7% |
| Revenue (ttm) | 17.56M +74.8% |
| Net Income | -147.39M |
| EPS | -14.10 |
| Shares Out | 15.94M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 569,899 |
| Open | 11.00 |
| Previous Close | 10.96 |
| Day's Range | 10.03 - 11.01 |
| 52-Week Range | 10.06 - 69.97 |
| Beta | 1.68 |
| Analysts | Strong Buy |
| Price Target | 46.25 (+358.83%) |
| Earnings Date | May 11, 2026 |
About TNXP
Tonix Pharmaceuticals Holding Corp., a fully integrated biopharmaceutical company, develops and commercializes therapies for central nervous system (CNS) disorders, immunology and immuno-oncology, infectious diseases, and rare diseases in the United States. The company offers TONMYA, a cyclobenzaprine HCl sublingual tablet for the treatment of fibromyalgia. It also markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults. In addition, the company develops TNX-102 SL, a cyclobenzaprine HCl sublingu... [Read more]
Financial Performance
In 2025, TNXP's revenue was $13.11 million, an increase of 29.85% compared to the previous year's $10.09 million. Losses were -$124.02 million, -4.63% less than in 2024.
Financial StatementsAnalyst Summary
According to 3 analysts, the average rating for TNXP stock is "Strong Buy." The 12-month stock price target is $46.25, which is an increase of 358.83% from the latest price.
News
Tonix Pharmaceuticals to Attend BTIG Infectious Disease Day 2026
BERKELEY HEIGHTS, N.J., June 11, 2026 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) ("Tonix" or the "Company"), a fully-integrated, commercial-stage biotechnology company, tod...
Tonix Pharmaceuticals secures second commercial agreement for Tonmya
Tonix Pharmaceuticals (TNXP) announced an agreement with a second group purchasing organization, or GPO, that provides coverage for Tonmya to an additional approximately 17M U.S. commercial lives, rep...
Tonix Pharmaceuticals Secures Second Commercial Payer Agreement for TONMYA®, Expanding Total Commercial Coverage to ~52 Million U.S. Lives
Agreement with second leading group purchasing organization (GPO), effective June 1, 2026, provides access to approximately 17 million additional U.S. commercial lives (10% of the ~177 million commerc...
Tonix Pharmaceuticals Holding Slides: Investor presentation
Tonix Pharmaceuticals Holding has posted slides in relation to its latest quarterly earnings report, which was published on June 1, 2026.
Tonix presents data from analysis of opioid use in adults with fibromyalgia
Tonix Pharmaceuticals (TNXP) presented data from a real-world claims analysis of opioid use in U.S. adults with fibromyalgia at the 2026 ASCP annual meeting, held May 26-29 in Miami Beach,…
Tonix Pharmaceuticals Presented Retrospective U.S. Real-World Claims Analysis of Opioid Use in Patients with Fibromyalgia at the 2026 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting
Real-world analysis of three years of closed claims data from Symphony Health, focused on the third year of the study (2023-2024), comprised of more than 261,000 U.S. adults with fibromyalgia
Tonix Pharmaceuticals publishes TNX-1500 data in Journal of Clinical Immunology
Tonix Pharmaceuticals (TNXP) announced the publication of a paper, “First-in-Human, Phase 1, Randomized, Double-Blind, Placebo-Controlled Study of TNX-1500, an Fc-Modified anti-CD154 Monoclonal Antibo...
Tonix Pharmaceuticals Announces Publication of Phase 1 Clinical Data of TNX-1500, an Fc-Modified anti-CD40L (CD154) Monoclonal Antibody, in the Peer-Reviewed Journal of Clinical Immunology
Phase 1 data support TNX-1500 as a potentially first-in-class, best-in-class, third-generation anti-CD40L monoclonal antibody for the prevention of kidney transplant rejection Phase 2 investigator-ini...
Tonix Pharmaceuticals Holding Slides: Investor presentation
Tonix Pharmaceuticals Holding has posted slides in relation to its latest quarterly earnings report, which was published on May 27, 2026.
Tonix Pharmaceuticals presents data from analysis of adults with fibromyalgia
Tonix Pharmaceuticals (TNXP) presented data from a real-world claims analysis characterizing U.S. adults with fibromyalgia in a poster at ISPOR 2026, the Professional Society for Health Economics and ...
Tonix Pharmaceuticals Presented Retrospective U.S. Real-World Claims Analysis Characterizing Patients with Fibromyalgia at The Professional Society for Health Economics and Outcomes Research (ISPOR) 2026 Annual Meeting
Real-world analysis of three years of closed claims data from Symphony Health focused on the third year of the study (2023-2024), comprised of more than 261,000 U.S. adults with fibromyalgia
Tonix Pharmaceuticals Holding Transcript: RBC Capital Markets Global Healthcare Conference 2026
Achieved first-in-class approval and strong early sales for a fibromyalgia drug, with accelerating Q2 trends and broadening payer coverage. Digital marketing and a growing sales force support expansion, while a large addressable market and pipeline for Lyme disease prevention offer significant long-term potential.
Tonix Pharmaceuticals to Present Retrospective U.S. Real-World Claims Analysis Characterizing Patients with Fibromyalgia at ISPOR 2026
BERKELEY HEIGHTS, N.J., May 14, 2026 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) ("Tonix" or the "Company"), a fully integrated, commercial biotechnology company, today anno...
Tonix Pharmaceuticals to Participate in Two Investor Conferences in May
BERKELEY HEIGHTS, N.J., May 12, 2026 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) ("Tonix" or the "Company"), a fully integrated, commercial biotechnology company, today anno...
Tonix Pharmaceuticals reports Q1 EPS ($2.93) vs. ($2.84) last year
Reports Q1 revenue $6.9M vs. $2.4M last year. “TONMYA is the first new fibromyalgia medicine in 15 years,” said Seth Lederman, M.D., Chief Executive Officer of Tonix Pharmaceuticals (TNXP). “TONMYA…
Tonix Pharmaceuticals Reports First Quarter 2026 Financial Results and Operational Highlights
In the first full quarter since launch, 2,145 healthcare providers prescribed TONMYA®, 3,588 patients initiated treatment, and ~5,400 prescriptions were filled
Tonix Pharmaceuticals Holding Quarterly report: Q1 2026
Tonix Pharmaceuticals Holding has published its Q1 2026 quarterly earnings report on May 11, 2026.
Tonix Pharmaceuticals Holding Earnings release: Q1 2026
Tonix Pharmaceuticals Holding released its Q1 2026 earnings on May 11, 2026, summarizing the period's financial results.
Tonix Pharmaceuticals secures commercial payer coverage for Tonmya
Tonix Pharmaceuticals (TNXP) announced an agreement with a leading group purchasing organization that provides coverage to approximately 35M U.S. commercial lives for Tonmya, a cyclobenzaprine HCl sub...
Tonix Pharmaceuticals Secures Commercial Payer Coverage for TONMYA®, Providing Access for ~35 Million U.S. Patients
Agreement with leading group purchasing organization (GPO) provides access to approximately 35 million U.S. commercial lives (20% of ~177 million commercial lives in the U.S.) TONMYA (cyclobenzaprine ...
Tonix Pharmaceuticals initiated with a Buy at TD Cowen
TD Cowen initiated coverage of Tonix Pharmaceuticals (TNXP) with a Buy rating and $22 price target The firm cites Tonmya’s potential in fibromyalgia for the Buy rating. Consultants indicate Tonmya’s…
Tonix Pharmaceuticals says on track to initiate Phase 2 study of TNX-4800
Tonix Pharmaceuticals (TNXP) announced presentation of Phase 1 data and plans for an adaptive Phase 2 field study of TNX-4800 for the prevention of Lyme disease in the U.S., at…
Tonix Pharmaceuticals Announces Presentation of Phase 1 Data and Plans for an Adaptive Phase 2 Field Study of TNX-4800 (anti-Borrelia OspA monoclonal antibody) for the Prevention of Lyme Disease at the 4th Annual Ticks and Tickborne Diseases Symposium at Johns Hopkins University
Company on track to initiate a randomized, double-blind, placebo-controlled, adaptive Phase 2 field study in the first half of 2027, pending FDA agreement Phase 2 field study expected to test a two-do...
Tonix Pharmaceuticals Presents Updates on Preclinical Immuno-Oncology Programs at the American Association for Cancer Research (AACR) Annual Meeting 2026
TNX-1700 (TFF2-albumin fusion protein) reversed aging-associated gastric inflammation and significantly attenuated tumor progression in aged gastric microenvironment in preclinical models TNX-1700 exh...
Tonix Pharmaceuticals publishes Tonmya study data findings
Tonix Pharmaceuticals (TNXP) announced the publication of a paper, “Steady-State Pharmacokinetic Properties of TNX-102 SL, a Sublingual Tablet Formulation of Cyclobenzaprine Hydrochloride, With Daily ...